Retatrutide: what it is and what the research actually shows

In “Doctor Explains Retatrutide: The Most Powerful GLP-1 Weight Loss Drug Yet”, Dr. Alex Tatem discusses Retatrutide. What he says, in short:

• He describes retatrutide as the first triple agonist GLP-1 drug, hitting GLP-1, GIP, and glucagon receptors, calling the added glucagon activity the 'secret sauce' that raises energy expenditure and fat oxidation on top of appetite suppression.
• He says its half life is about 6 to 7 days, allowing once weekly injections like semaglutide and tirzepatide.
• From the phase 2 obesity trial at 48 weeks, he reports 8 mg a week produced a mean 22.8% weight loss and 12 mg produced 24.2%, with on the top dose 100% of patients losing at least 5% of body weight, 93% losing at least 10%, and 83% losing over 15%, and by 24 weeks top doses were already at 17.3 to 17.5% loss.
• In diabetic patients he says it dropped A1C by 2 points at 24 weeks on the 12 mg dose versus 1.4 with dulaglutide, and produced 16.8 to 16.9% body weight loss at 36 weeks.
• On side effects he reports about 82% of retatrutide patients had some side effect versus 70% on placebo, with nausea in 27%, diarrhea in 13%, vomiting in 10%, constipation in 9%, decreased appetite in 18%, a dose dependent heart rate rise, cardiac arrhythmias in 6% versus 3% on placebo, biliary disorders in 1%, and pancreatitis in under 1%.
• He says it is not yet approved, with phase 3 completion targeted for May 2026 and earliest realistic US approval in 2027, and he warns against buying it from gray market suppliers due to inconsistent dosing and contamination risk.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Retatrutide Dosing Explained (Doctor Breaks Down the Data)”, Dr. Alex Tatem discusses Retatrutide. What he says, in short:

• He calls retatrutide the first drug to act on three receptors at once, GLP-1, GIP, and glucagon, which he nicknames the triple G.
• He reports Lilly's Triumph 1 phase three results from May 21, 2026: average body weight loss at 80 weeks was 28.3% at the 12 mg dose, 25.9% at 9 mg, and 19% at 4 mg, versus 2.2% on placebo, with everyone starting at 2 mg and stepping up every 4 weeks.
• He says even the lowest 4 mg dose beat semaglutide's roughly 15% ceiling from the Wegovy trial, while cautioning these are cross-trial comparisons rather than a head to head study.
• He flags three side effects he ties to retatrutide specifically: a resting heart rate increase of about six to seven beats per minute at the top dose (some sources citing up to around 10), skin tingling or burning (dysesthesia) in roughly 5 to 13% of patients, and anecdotal insomnia reports that aren't confirmed trial findings.
• He warns that the retatrutide people are currently injecting is unregulated, Chinese-made research chemical, with real risk of mis-dosed vials, contamination, or at-home reconstitution errors, and says he's reporting on this gray market use, not recommending it.
• He predicts real-world dosing will likely settle around 4 to 9 mg once a pharmacy version is approved, which he estimates at 2027 at the earliest.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Retatrutide Side Effects - Dr Reveals the BAD, The UGLY”, Dr. Ashley Froese discusses Retatrutide. What she says, in short:

• She describes retatrutide as a triple receptor agonist hitting GLP-1, GIP, and glucagon receptors at once, unlike other weight loss peptides that only pull one or two of those levers.
• She explains early fatigue as the body shifting from glucose to fat oxidation while insulin drops, which also causes the kidneys to dump sodium and water, and says this is the drug working, not a malfunction, recommending electrolytes and patience with titration.
• She lists GI side effects, nausea, vomiting, diarrhea, constipation, bloating, and sulfur burps, from GLP-1 slowing gastric emptying, and suggests smaller meals, less liquid with meals, digestive enzymes, and magnesium oxide at night.
• She covers musculoskeletal effects, muscle cramps from electrolyte loss, less understood joint pain, and muscle loss, and recommends 150 to 200 g of protein a day for men and 100 to 130 g for women along with resistance training.
• She says resting heart rate can rise by about 5 to 10 beats per minute from the glucagon component, generally not alarming on its own, and describes allodynia, skin pain from light touch, from glucagon receptors on sensory neurons, with most people reducing the dose for a few weeks before retitrating up.
• She flags two rarer but serious risks, gallstones from rapid weight loss and pancreatitis, saying severe unrelenting upper abdominal pain radiating to the back needs immediate medical evaluation.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Dr. Explains Why Retatrutide is KING of Fat Loss Peptides”, Dr. Ashley Froese discusses Retatrutide. What she says, in short:

• She describes retatrutide as combining GLP-1, GIP, and glucagon receptor agonism, calling it the current best version of the GLP-1 class because it raises metabolism while cutting fat rather than just suppressing appetite.
• She explains the glucagon component causes mitochondrial uncoupling that wastes energy as heat, which she says helps prevent the metabolic slowdown that normally stalls weight loss during dieting.
• She cites trial data showing up to 40% of weight lost on these GLP peptide blends can be lean muscle, and advises eating at least 1 gram of protein per pound of lean body mass and tracking muscle mass.
• She cites a 5 to 10 beats per minute increase in resting heart rate seen in research, tied to glucagon receptors on the heart's pacemaker, and says this could matter for people at risk of arrhythmia.
• She says about 20% of participants at the high 12 mg dose reported allodynia, skin feeling sunburned, which may be temporary and reduced by slow dose titration.
• She states trial doses were 2, 4, 6, 9, and 12 mg with 4 week intervals before increasing, flags pancreatitis risk of less than 0.5% in trials and gallstone risk from rapid weight loss, and says retatrutide is still in clinical trials and not yet approved.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “A Surprising New Weight Loss Peptide: Retatrutide | Epi 41 #LastingWeightLossPodcast”, Dr. Jones, DC discusses Retatrutide. What he says, in short:

• He frames retatrutide as the triple agonist whose third receptor, glucagon, is what makes it a different kind of transition than moving from semaglutide to tirzepatide was.
• He is explicit that it has not passed phase three, and says that any phase three approved medication should always be the first option when it is available.
• He says his providers always recommend tirzepatide and semaglutide before retatrutide, and that he has not yet hit a situation where a patient needed it.
• He walks through the phase two cardiac signal himself, describing a trial of about 338 people with under 4 percent adverse events, mostly mild to moderate tachycardia, and one more serious QT prolongation case he says was likely tied to the patient also being on Zofran.
• He says his providers have self-imposed a contraindication for people with tachycardia or arrhythmia issues based on what they saw in phase two, and expects the glucagon receptor to add new contraindications on top of the existing GLP-1 ones such as gastroparesis, pancreatitis, biliary disease and active gallstones.
• He says most people start at 1 milligram following the trial escalation of 1, 2, 4 and 8, while his practice will not put anyone past about 4 milligrams and almost never goes there.
• He discloses his own use as 2 milligrams roughly once every three weeks, and says the handful of patients who have tried it do not go past two.
• He warns hard against research and black market retatrutide, saying a lot of what is already in circulation comes from those sources and that he wants it coming from 503A or 503B pharmacies instead.

in our practice we won't put anybody past like 4 milligrams would be the highest that we'd ever put anybody on and that almost never happens

I think any phase three approved medication when available should always be the option first

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Stack Retatrutide & These 2 Peptides to STOP The Aging Clock (GHK-Cu, MOTS-c)”, Dr. Jones, DC discusses Retatrutide. What he says, in short:

• He asks viewers to look at retatrutide as a metabolic reboot rather than only a weight loss agent, assigning it the metabolic hand of his three-handed aging clock.
• He says the mistake he sees constantly is people treating it like a sledgehammer and pushing for the highest dose their clinic or their black market source will supply.
• He says pushing it hard raises energy expenditure and fat oxidation and puts the body under real caloric stress that can feel like an aggressive fast, and can backfire the same way.
• He offers a clinic anecdote of a patient who came off 14 months of tirzepatide, jumped straight to a high retatrutide dose, hit hard nausea by week two and crashed out by week six having lost muscle he did not want to lose.
• He says the protocol that works in his clinical experience is low-dose retatrutide run consistently, because in his framing the metabolic hand responds to a steady signal rather than aggression.
• He warns that running retatrutide on low protein intake is a setup for real muscle loss that is slow and frustrating to rebuild.
• He says people who come in disappointed usually crashed their protein and called it a stalled run rather than the compound failing.

The protocol that actually works, low-dose retatrutide, ran consistently.

In our clinical experience, the metabolic hand doesn't respond to aggression.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.